Literature DB >> 26803518

Inhibitor of growth-4 is a potential target for cancer therapy.

Shuping Yuan1,2, Jianhua Jin1, Juanjuan Shi3, Yongzhong Hou4,5.   

Abstract

The inhibitor of growth-4 (ING-4) belongs to the inhibitor of growth (ING) family that is a type II tumor suppressor gene including five members (ING1-5). As a tumor suppressor, ING4 inhibits tumor growth, invasion, and metastasis by multiple signaling pathways. In addition to that, ING4 can facilitate cancer cell sensitivity to chemotherapy and radiotherapy. Although ING4 loss is observed for many types of cancers, increasing evidences show that ING4 can be used for gene therapy. In this review, the recent progress of ING4 regulating tumorigenesis is discussed.

Entities:  

Keywords:  Cell proliferation; DNA repair; ING4; NFκB; p53

Mesh:

Substances:

Year:  2016        PMID: 26803518     DOI: 10.1007/s13277-016-4842-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  79 in total

Review 1.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.

Authors:  J Conner; L Braidwood
Journal:  Cancer Gene Ther       Date:  2012-05-18       Impact factor: 5.987

3.  Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-κB signaling pathway.

Authors:  Shijie Li; Tianli Fan; Hongtao Liu; Jiangtao Chen; Changjiang Qin; Xuequn Ren
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

Review 4.  Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4.

Authors:  Abdullah Ozer; Richard K Bruick
Journal:  Cell Cycle       Date:  2005-09-19       Impact factor: 4.534

Review 5.  NF-kappaB activation: the I kappaB kinase revealed?

Authors:  I Stancovski; D Baltimore
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

6.  MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.

Authors:  Marek Mraz; Dasa Dolezalova; Karla Plevova; Katerina Stano Kozubik; Veronika Mayerova; Katerina Cerna; Katerina Musilova; Boris Tichy; Sarka Pavlova; Marek Borsky; Jan Verner; Michael Doubek; Yvona Brychtova; Martin Trbusek; Ales Hampl; Jiri Mayer; Sarka Pospisilova
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

7.  Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis.

Authors:  Yufeng Xie; Haifeng Zhang; Weihua Sheng; Jim Xiang; Zhenmin Ye; Jicheng Yang
Journal:  Cancer Lett       Date:  2008-09-11       Impact factor: 8.679

8.  Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.

Authors:  Feng Fang; Lai-Bang Luo; Yi-Ming Tao; Fan Wu; Lian-Yue Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02       Impact factor: 4.254

9.  Experimental studies on the inhibition of adenovirus-ING4-OSM therapy on nasopharyngeal carcinoma proliferation in vitro and in vivo.

Authors:  Zeli Han; Chengyong Zhou; Baochun Sun; Qinghong Yan; Jinghong Zhang
Journal:  Cell Biochem Biophys       Date:  2014-12       Impact factor: 2.194

10.  Functional genomics screening utilizing mutant mouse embryonic stem cells identifies novel radiation-response genes.

Authors:  Kimberly Loesch; Stacy Galaviz; Zaher Hamoui; Ryan Clanton; Gamal Akabani; Michael Deveau; Michael DeJesus; Thomas Ioerger; James C Sacchettini; Deeann Wallis
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

View more
  4 in total

1.  Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.

Authors:  A Galal El-Shemi; A Mohammed Ashshi; E Oh; B-K Jung; M Basalamah; A Alsaegh; C-O Yun
Journal:  Gene Ther       Date:  2017-09-19       Impact factor: 5.250

2.  Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus.

Authors:  Jiamin Peng; Shibing Wang; Weimin Fan; Shuangshuang Li; Yi Wu; Xiaozhou Mou; Jianchao Wang; Xiangmin Tong
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.345

3.  ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis.

Authors:  Fuliang Qian; Qingqing Hu; Yali Tian; Jie Wu; Dapeng Li; Min Tao; Lei Qin; Bairong Shen; Yufeng Xie
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

4.  miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway.

Authors:  Xiangqin Tang; Yanjun Ding; Xiaoqing Wang; Xiuzhen Wang; Lin Zhao; Hongmei Bi
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.